Moody Aldrich Partners LLC Takes $1.13 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Moody Aldrich Partners LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 58,688 shares of the company’s stock, valued at approximately $1,125,000. Moody Aldrich Partners LLC owned approximately 0.07% of Viridian Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Great Point Partners LLC boosted its stake in Viridian Therapeutics by 50.0% during the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after buying an additional 250,000 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of Viridian Therapeutics during the third quarter valued at $8,917,000. JPMorgan Chase & Co. lifted its stake in Viridian Therapeutics by 218.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock worth $9,108,000 after acquiring an additional 274,641 shares in the last quarter. Novo Holdings A S boosted its position in Viridian Therapeutics by 19.3% during the 3rd quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock worth $54,259,000 after acquiring an additional 385,000 shares during the period. Finally, Barclays PLC grew its stake in Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after acquiring an additional 66,550 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have recently issued reports on VRDN. Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Royal Bank of Canada lifted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. TD Cowen started coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating on the stock. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $19.43 on Thursday. The stock has a market capitalization of $1.54 billion, a PE ratio of -4.51 and a beta of 1.13. The stock has a 50-day simple moving average of $19.42 and a 200 day simple moving average of $19.40. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics, Inc. has a twelve month low of $11.40 and a twelve month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.08 million. Research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.